(1)Pemafibrate, also known as K-877 and (R)-K 13675, is a PPAR alpha agonist. (R)-K-13675 decreases the secretion of inflammatory markers without affecting cell proliferation or tube formation. (2)Pemafibrate, marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.In 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. It is available in 0.1mg tablets.
Contact：Wuhan Sun-shine Bio-technologyCorporation Limited Add: Building C16, No.388Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790 Web:http://www.sun-shinechem.com
| 
